

**Medical Developments International Limited
Chairman's and CEO's presentation
Annual General Meeting
5th November 2008**

Chairman's address

Ladies and Gentlemen, your Board is conscious that the MVP share price has underperformed the market and our pharma/biotech peers.

On the positive side, we have a product in the market; we have no debt; we are making profits with cash in the bank and the Company offers have plenty of upside.

Our NPAT for FY08 was below FY07 even though our revenue was up, but we invested significantly in registrations, international market development, regulatory development, and marketing and this impacted our profit. Some of our business development has been slower than we had hoped, due to the complexities of international markets; but all is still on track for significant business expansion and profit growth over the next few years.

The Company is on very sound footing operationally and financially and we are cautiously optimistic that FY09 will see a significant improvement in our revenue, profits and company growth.

We have already made public statements about the key drivers of future growth; Middle East sales; New Zealand sales; veterinary use; and including our products in doctors bags under the PBS. All of these possibilities are well advanced.

I will now ask our CEO Chris Rossidis to say a few words and put some meat on the bones of what I have said.

CEO's Address

FY08 has been a watershed year for MVP as we made significant advances in many areas. As I work through my presentation you will notice that many of the achievements listed were as promised at the 2007 AGM.

The strategy in FY08 was to focus on activities that would deliver long term sustainable growth, and this continues to be the motivation and direction for management in FY09. Our business objectives for FY09 are for double digit growth for our core business in Australia and NZ and the expansion in sales in Pentrox and Medical Devices overseas. We expect that profit in FY09 will grow substantially from FY08 as costs are expected to be stable as a proportion of revenue and no significant one off costs are expected as was experienced in the FY08.

I would now like to summarise the achievements of the year just past and the focus of the year ahead.

For personal use only

Highlights in FY08 include:

- Sales Growth - increase in sales (+24%)
Penthrox growth of 36% driven by:
 - Australia – Aesthetics, Dentistry and Hospitals
 - NZ – Ambulance and Hospitals
 - Middle East launch and sales
- Registration program expansion
 - Penthrox submitted for registration in 11 new countries in FY08
 - Currently 18 countries where Penthrox is under review
 - Western European strategy: clear pathway
- Continued development of the Penthrox clinical programme
 - Long term safety study in WA
 - Bone Marrow Biopsy study at the Peter Mac
 - Emergency Medicine study in Belgium
- Veterinary Registration of Methoxyflurane in the US
 - Audit of our manufacturing facility in FY08 came at a significant cost
 - US, FDA inspection of MVP manufacturing plant completed early in calendar 2008
 - Approval expected very shortly.
- Submission to the Pharmaceutical Benefits Authority (PBS) for Penthrox to be used in General Practice through Doctor's Bag inclusion
- Successful 3 year extension of the PHARMAC (NZ reimbursement Authority) tender for MVPs range of Asthma Products
- Growth of the MVP oxygen range of Products by 28%

Our strategic direction for FY09 is to

- Maximize sales of Penthrox in:
 - Australia through local partnerships and PBS listing
 - NZ – increase usage in the Ambulance service and Hospitals
 - Overseas countries
 - Middle East through continued promotion
 - Launch into new countries
- Registration program expansion
 - Submit for Penthrox registration in new countries
 - Asia, South America and Eastern Europe
- Western European Strategy
 - Continue the development of the Penthrox clinical programme
- Maximize the sales of Methoxyflurane for Veterinary use in the USA.
- Expansion of sales of our Asthma Range of Products into new countries
 - European, South America and Asia